Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Jackson Square Partners LLC

Jackson Square Partners LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 16.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,045 shares of the company's stock after selling 12,215 shares during the quarter. Medpace makes up approximately 2.2% of Jackson Square Partners LLC's holdings, making the stock its 22nd largest holding. Jackson Square Partners LLC owned 0.20% of Medpace worth $20,281,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of MEDP. Centaurus Financial Inc. grew its holdings in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after purchasing an additional 29 shares during the period. Lindbrook Capital LLC boosted its position in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC boosted its position in Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. increased its holdings in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its position in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock valued at $243,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Remove Ads

Medpace Price Performance

NASDAQ:MEDP traded down $4.25 during mid-day trading on Friday, reaching $312.36. The stock had a trading volume of 343,137 shares, compared to its average volume of 298,736. The company has a market capitalization of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The stock's 50 day simple moving average is $335.90 and its two-hundred day simple moving average is $339.15.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus target price of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.